SlideServe
Télécharger Obtenir Pro
Menu
Accueil Pro
Préférences
ApparenceLight Aide et commentaires
© SlideServe · v2026

Controversies in Iron Chelation in Myelodysplastic Syndromes

gaura avatar
gaura
8 diapositives · 225 Views · Jul 13, 2014

This article explores the complex issues surrounding iron chelation therapy in patients with Myelodysplastic Syndromes (MDS), focusing on its effects on overall survival and the risk of leukaemic evolution. It analyzes data from over 900 patients, emphasizing the detrimental impact of iron overload and transfusion dependency on patient outcomes. The findings indicate that appropriate iron chelation therapy significantly improves survival rates, particularly in heavily transfused lower-risk MDS patients. The study identifies independent predictors of survival and non-leukaemic causes of death related to iron overload.

#controversies in iron chelation in myelodysplastic syndromes #controversies in iron chelation in myelodysplastic syndromes ppt #powerpoint #presentation
Controversies in Iron Chelation in Myelodysplastic Syndromes - slide 1
01 / 8Controversies in Iron Chelation in Myelodysplastic Syndromes
1 / 17

Télécharger la présentation

Controversies in Iron Chelation in Myelodysplastic Syndromes
Une image / un lien ci-dessous est fourni (tel quel) pour télécharger la présentation

Politique de téléchargement : le contenu du site vous est fourni TEL QUEL pour votre information et votre usage personnel ; il ne peut être vendu, concédé sous licence ni partagé sur d’autres sites sans l’accord de son auteur.Le contenu vous est fourni TEL QUEL, pour votre information et votre usage personnel uniquement. Téléchargez la présentation en cliquant sur ce lien. Lors du téléchargement, si vous ne parvenez pas à télécharger une présentation, l’éditeur a peut-être supprimé le fichier de son serveur.Pendant le téléchargement, si vous ne parvenez pas à obtenir une présentation, le fichier a peut-être été supprimé par l’éditeur.

F I N

Plus de contenu associé

Transcription de la présentation

  1. Aristoteles Giagounidis, MD, PhDDepartment of Haematology and OncologySt. Johannes Hospital Duisburg, Germany Heather A. Leitch, MD, PhD, FRCPCHematologistDepartment of Medicine, Division of HematologySt. Paul’s HospitalUniversity of British ColumbiaVancouver, British Columbia, Canada Controversies in Iron Chelation in Myelodysplastic Syndromes

  2. Iron Overload and Transfusion Dependency Independent Impact on Overall Survival and Leukaemic Evolution in 902 Patients with MDS HRP Value • Overall survival • Iron overload 52.4 <.0001 • Transfusion dependency 8.8 <.0001 • Risk for evolution to AML • Iron overload 6.6 <.0001 • Transfusion dependency 3.5 <.003 Sanz G, et al. 50th Annual ASH Meeting; December 6-9, 2008. Abstract 640.

  3. Independent Predictors of Survival in MDS Median SurvivalP value Transfusion- Dependent 34 mos <.001 Independent 56 mos Ferritin High (>1,000 ng/mL) 34 yrs <.001 <1,000 53 yrs Arnan M, et al. 15th Congress of EHA, June 2010. Abstract 314.

  4. Nonleukaemic Causes of Death in MDS and Relationship to Iron Overload • Cardiac failure (CHF) 51% • Infection 31% • Haemorrhage 8% • Hepatic cirrhosis 8% • Unidentified 2% Low-risk MDS: Cardiac failure is significantly more common in transfused than nontransfused patients (P=.01) Malcovati L, et al. J Clin Oncol. 2005;23:7594-7603.

  5. Iron Chelation and Overall Survival in Low/Int-1 MDS • Median overall survival • No chelation therapy – 53 mos • Chelation therapy – 124 mos (p<.0003) • Adequate chelation was the strongest factor associated with better overall survival in heavily transfused lower risk MDS patients 97 low or int-1 IPSS regularly transfused patients: 44 (45%) not chelated; 53 (55%) chelated for >6 mos Rose C, et al. Leuk Res. 2010;34:864-870.

  6. Hematologic Improvement in MDS Patients with Iron Chelation Therapy Pts with Minor Erithroid Response* After 6 mos 1/8 After 9 mos 2/8 After 12 mos 2/8 Total response rate 5/8 (60%) 8 MDS patients received ● Deferasirox 5-20 mg/kg/day, or ● Desferrioxamine 30 mg/kg/sc 3-4 times/week *Minor response = 50% reduction in RBC transfused Molteni A, et al. 15th Congress of EHA, June 2010. Abstract 1410.

  7. Transfusion-dependent patients Ferritin levels >1000 ng/mL Low-risk MDS (IPSS low or Int-1; WHO RA and RARS and 5q-) Expected overall survival ≥1 year Candidates for allograft Need to preserve organ function Absence of comorbidities severely limiting prognosis 2008 Consensus Statement on Iron Overload in MDS Patients most likely to benefit from the treatment of iron overload Bennett JM, et al. Am J Hematol. 2008;83:858-861.

  8. Thank you for participating in this activity Please remember to take the posttest